Dicerna Pharmaceuticals (DRNA) – Investment Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of Dicerna Pharmaceuticals (NASDAQ: DRNA) recently:

  • 3/14/2019 – Dicerna Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “
  • 3/13/2019 – Dicerna Pharmaceuticals had its price target raised by analysts at B. Riley from $21.00 to $24.00. They now have a “buy” rating on the stock.
  • 3/13/2019 – Dicerna Pharmaceuticals had its price target raised by analysts at SunTrust Banks, Inc. to $26.00. They now have a “buy” rating on the stock.
  • 3/12/2019 – Dicerna Pharmaceuticals was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 3/12/2019 – Dicerna Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $13.00 price target on the stock. According to Zacks, “Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “
  • 3/6/2019 – Dicerna Pharmaceuticals was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 2/26/2019 – Dicerna Pharmaceuticals is now covered by analysts at Cowen Inc. They set an “outperform” rating on the stock.
  • 2/25/2019 – Dicerna Pharmaceuticals was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 2/14/2019 – Dicerna Pharmaceuticals was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 1/22/2019 – Dicerna Pharmaceuticals was upgraded by analysts at Chardan Capital from a “neutral” rating to a “buy” rating. They now have a $18.00 price target on the stock.
  • 1/17/2019 – Dicerna Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “

Dicerna Pharmaceuticals stock opened at $12.31 on Friday. The company has a market cap of $720.16 million, a P/E ratio of -10.26 and a beta of 2.40. Dicerna Pharmaceuticals Inc has a one year low of $8.71 and a one year high of $17.98.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its earnings results on Monday, March 11th. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.06). The company had revenue of $1.54 million for the quarter, compared to the consensus estimate of $8.38 million. Dicerna Pharmaceuticals had a negative return on equity of 65.91% and a negative net margin of 1,438.68%. On average, analysts forecast that Dicerna Pharmaceuticals Inc will post -0.66 earnings per share for the current fiscal year.

Institutional investors have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Dicerna Pharmaceuticals by 512.2% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,459 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 2,894 shares in the last quarter. Legal & General Group Plc increased its holdings in Dicerna Pharmaceuticals by 38.7% during the 4th quarter. Legal & General Group Plc now owns 9,186 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 2,561 shares in the last quarter. Bank of America Corp DE increased its holdings in Dicerna Pharmaceuticals by 30.3% during the 4th quarter. Bank of America Corp DE now owns 10,596 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 2,465 shares in the last quarter. TD Asset Management Inc. acquired a new stake in Dicerna Pharmaceuticals during the 4th quarter valued at $169,000. Finally, State Board of Administration of Florida Retirement System increased its holdings in Dicerna Pharmaceuticals by 19.9% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 18,234 shares of the biopharmaceutical company’s stock valued at $195,000 after purchasing an additional 3,024 shares in the last quarter. Institutional investors and hedge funds own 92.81% of the company’s stock.

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.

Recommended Story: Understanding the different types of bonds

Receive News & Ratings for Dicerna Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.